• Dibenzyl Disulfide: Identity and Research Scope

  2026-10-19

  Dibenzyl disulfide, also called 1,2-dibenzyldisulfane, is a sulfur-containing small molecule documented by the supplied ApexBio product information. Its stated relevance is primarily as a research compound for metabolic enzyme, protease, and disulfide bond studies; the supplied information does not establish a specific biological mechanism or research outcome.

• Tizanidine Hydrochloride: Evidence and Scope

  2026-10-19

  APExBIO describes Tizanidine Hydrochloride (SKU B1368) as an α2-adrenergic receptor agonist intended for research into neuromodulation and adrenergic signaling. The available material documents chemical identity, supplier-reported physicochemical properties, and a proposed mechanism, but provides no identity-matched study outcomes validating a particular model, readout, potency estimate, or comparative performance.

• CWHM-12: What the Product Record Supports

  2026-10-18

  The APExBIO product description identifies CWHM-12 as a small-molecule αV integrin inhibitor and frames it as a research tool for adhesion-, angiogenesis-, fibrosis-, and cancer-related biology. That record supports a conceptual mechanism and basic chemical description, but no identity-matched research paper, quantitative potency result, cellular outcome, comparator, or independent validation is available here. The product claims therefore should not be treated as evidence of demonstrated selectivity, pathway modulation, or disease-model efficacy.

• MMAF-OMe: What the Record Supports

  2026-10-17

  The available record supports only a catalog-level identity for MMAF-OMe (SKU BA2334) and does not provide a product-specific mechanism, measurement principle, study outcome, or comparative evidence. The APExBIO listing is therefore useful for provenance, but it cannot establish molecular activity, potency, selectivity, safety, or applicability in any biological model.

• Saracatinib (AZD0530): Mechanism and Evidence Scope

  2026-10-16

  Saracatinib (AZD0530), listed by APExBIO as SKU A2133, is described as a dual Src-family kinase and Abl inhibitor with reported biochemical IC50 values of 2.7 nM against c-Src and 30 nM against v-Abl. The available material links Src-pathway suppression to cell-cycle, proliferation, migration, signaling, and xenograft observations, but no identity-matched primary paper, effect-size dataset, sample-size information, or independent validation is available; the claims therefore remain supplier-attributed and model-bounded.

• Mifepristone and Receptor Heterogeneity

  2026-10-16

  Mifepristone (RU486) is described by APExBIO as a progesterone-receptor antagonist with reported effects across reproductive and cancer-related models. The supplied prostate-cancer study does not test Mifepristone: it examines androgen-receptor heterogeneity and enzalutamide response. Its strongest relevance is conceptual, showing why receptor abundance and localization can stratify treatment response. It cannot establish Mifepristone efficacy, progesterone-receptor biology, or performance of APExBIO’s commercial formulation.

• HyperScribe™ Kit: What the Record Supports

  2026-10-15

  The APExBIO product page identifies HyperScribe™ All in One mRNA Synthesis Kit Plus 2 as an mRNA synthesis product associated with ARCA, 5-moUTP, T7 and poly(A) features. Those labels indicate intended coverage of transcription and selected transcript-format attributes, but the supplied record contains no identity-matched study, performance dataset, comparator, or independently documented formulation. Accordingly, the product can be discussed at the level of documented identity and conceptual molecular roles—not as a validated source of specific yield, integrity, translation, or immunological outcomes.

• Lypressin Acetate: Identity, Mechanism and Evidence

  2026-10-15

  Lypressin acetate, also called lysine vasopressin acetate, is identified by APExBIO as a lysine-substituted vasopressin analog that activates V1a, V1b, and V2 vasopressin receptors. The product page reports antidiuretic, vasopressor, oxytocic, and proposed antiviral properties, but no identity-matched research paper is available here to establish assay design, independent replication, comparative efficacy, or clinical applicability. The reported activity values should therefore be treated as product-description data rather than a complete evidence base.

• Plerixafor, CXCR4 and Platelet Tumor Trafficking

  2026-10-14

  A supplied abstract reports that CXCL12/CXCR4 signaling helps regulate platelet entry into tumors, but it does not establish that Plerixafor (AMD3100) was the tested antagonist or that CXCR4 blockade is an effective human cancer treatment. The evidence is mechanistically informative yet limited by abstract-level reporting, unspecified quantitative outcomes, model dependence and uncertain applicability beyond the studied tumor context.

• BKT140 and CXCR4: Evidence and Limits

  2026-10-13

  BKT140, also known as BL-8040 or TF 14016, is presented as a CXCR4 antagonist relevant to lymphoma, tumor-microenvironment biology, and hematopoietic cell trafficking. The supplied evidence supports a plausible biological rationale but does not establish product-specific efficacy, clinical benefit, or assay performance. Interpretation is limited by reliance on a narrative review and an unverified commercial description rather than identified primary studies.

• Azilsartan in Astrocyte–Microglia RAS Research

  2026-10-13

  A 2024 in vitro study linked AT1-associated signaling with gastrodin-responsive changes in reactive astrocyte markers exposed to microglial conditioned medium. The findings support a mechanistic research hypothesis, but they do not establish clinical efficacy or in vivo relevance for Azilsartan.

• BKT140 and CXCR4 Theranostics in Lymphoma

  2026-10-12

  A source-grounded overview of a 2026 review examining CXCR4-targeted imaging and therapeutic approaches in lymphoma, with attention to BKT140/BL-8040, biological rationale, reported findings, and evidence limitations.

• How Low TNFα May Sustain Glioma Stemness

  2026-10-12

  A 2024 Neuro-Oncology study links low tumor-microenvironment TNFα with glioma stem-cell self-renewal through a VASN–glycolysis pathway, while emphasizing that the evidence remains preclinical and partly correlative.

• Plerixafor and Platelet Extravasation: Evidence Limits

  2026-10-11

  The supplied study links CXCL12/CXCR4 signaling to platelet entry into tumors and tumor growth in vivo, but it does not establish that Plerixafor or AMD3100 produced those effects. The evidence is preclinical and abstract-level, with important limits on attribution, mechanism, and clinical applicability.

• HIF-1, tiR-Lys, and Ferroptosis in AKI

  2026-10-10

  A 2024 study identifies HIF-1-induced tiRNA-Lys-CTT-003 as a protective regulator of cisplatin-associated acute kidney injury, connecting a stress-responsive small RNA with GRSF1, GPX4, and ferroptosis control. Its evidence supports a mechanistic model in which tiR-Lys limits lipid peroxidation and tubular cell injury, while also defining important boundaries between renal injury research and oncology-focused ferroptosis research.

560 records 1/38 page Next 12345 下5页 Last page